There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Inherited retinal diseases, such as retinitis pigmentosa (RP), can be caused by thousands
of different mutations, a small number of which have been successfully treated with
gene replacement. However, this approach has yet to scale and may not be feasible
in many cases, highlighting the need for interventions that could benefit more patients.
Here, we found that microglial phagocytosis is upregulated during cone degeneration
in RP, suggesting that expression of “don’t-eat-me” signals such as CD47 might confer
protection to cones. To test this, we delivered an adeno-associated viral (AAV) vector
expressing CD47 on cones, which promoted cone survival in 3 mouse models of RP and
preserved visual function. Cone rescue with CD47 required a known interacting protein,
signal regulatory protein α (SIRPα), but not an alternative interacting protein, thrombospondin-1
(TSP1). Despite the correlation between increased microglial phagocytosis and cone
death, microglia were dispensable for the prosurvival activity of CD47, suggesting
that CD47 interacts with SIRPα on nonmicroglial cells to alleviate degeneration. These
findings establish augmentation of CD47/SIRPα signaling as a potential treatment strategy
for RP and possibly other forms of neurodegeneration.
Background Phase 1 studies have shown potential benefit of gene replacement in RPE65 -mediated inherited retinal dystrophy. This phase 3 study assessed the efficacy and safety of voretigene neparvovec in participants whose inherited retinal dystrophy would otherwise progress to complete blindness. Methods In this open-label, randomised, controlled phase 3 trial done at two sites in the USA, individuals aged 3 years or older with, in each eye, best corrected visual acuity of 20/60 or worse, or visual field less than 20 degrees in any meridian, or both, with confirmed genetic diagnosis of biallelic RPE65 mutations, sufficient viable retina, and ability to perform standardised multi-luminance mobility testing (MLMT) within the luminance range evaluated, were eligible. Participants were randomly assigned (2:1) to intervention or control using a permuted block design, stratified by age (<10 years and ≥10 years) and baseline mobility testing passing level (pass at ≥125 lux vs <125 lux). Graders assessing primary outcome were masked to treatment group. Intervention was bilateral, subretinal injection of 1·5×10 11 vector genomes of voretigene neparvovec in 0·3 mL total volume. The primary efficacy endpoint was 1-year change in MLMT performance, measuring functional vision at specified light levels. The intention-to-treat (ITT) and modified ITT populations were included in primary and safety analyses. This trial is registered with ClinicalTrials.gov, number NCT00999609, and enrolment is complete. Findings Between Nov 15, 2012, and Nov 21, 2013, 31 individuals were enrolled and randomly assigned to intervention (n=21) or control (n=10). One participant from each group withdrew after consent, before intervention, leaving an mITT population of 20 intervention and nine control participants. At 1 year, mean bilateral MLMT change score was 1·8 (SD 1·1) light levels in the intervention group versus 0·2 (1·0) in the control group (difference of 1·6, 95% CI 0·72–2·41, p=0·0013). 13 (65%) of 20 intervention participants, but no control participants, passed MLMT at the lowest luminance level tested (1 lux), demonstrating maximum possible improvement. No product-related serious adverse events or deleterious immune responses occurred. Two intervention participants, one with a pre-existing complex seizure disorder and another who experienced oral surgery complications, had serious adverse events unrelated to study participation. Most ocular events were mild in severity. Interpretation Voretigene neparvovec gene replacement improved functional vision in RPE65 -mediated inherited retinal dystrophy previously medically untreatable. Funding Spark Therapeutics.
Publisher:
American Society for Clinical Investigation
ISSN
(Electronic):
2379-3708
Publication date
(Electronic, pub):
23
August
2021
Publication date
(Electronic, collection):
23
August
2021
Publication date PMC-release: 23
August
2021
Volume: 6
Issue: 16
Electronic Location Identifier: e150796
Affiliations
Department of Genetics, Blavatnik Institute, and Department of Ophthalmology, Harvard
Medical School, Boston, Massachusetts, USA. Howard Hughes Medical Institute, Chevy
Chase, Maryland, USA.
Author notes
Address correspondence to: Constance L. Cepko, Harvard Medical School, 77 Avenue Louis
Pasteur, NRB Room 360, Boston, Massachusetts 02115, USA. Phone: 617.432.7618; Email:
cepko@
123456genetics.med.harvard.edu
.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.